Drugs.com - Monthly Update May 2026
In this May 2026 Monthly Update edition, we cover several new FDA approvals and a major prescription-to-OTC switch expanding therapeutic options.
- Veppanu (vepdegestrant): The first PROTAC (PROteolysis TArgeting Chimera) therapy to be approved for ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer based on strong progression-free survival clinical data.
- Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrrolate): A triple-combination inhalation aerosol approved for the long-term maintenance treatment of adult asthma.
- Xocova (ensitrelvir): The first oral antiviral tablet indicated for post-exposure prophylaxis (PEP) to prevent COVID-19 following exposure.
- Baxfendy (baxdrostat): A first-in-class oral aldosterone synthase inhibitor approved to treat uncontrolled hypertension in combination with other agents.
- Differin Epiduo Acne Gel (adapalene/benzoyl peroxide): A prescription combination acne treatment newly approved for over-the-counter (OTC) use.
- Zaynich (cefepime/zidebactam): An intravenous antibiotic approved for adults suffering from complicated urinary tract infections and pyelonephritis.
- Immgolis (golimumab-sldi): The first interchangeable biosimilar to Simponi approved for adult rheumatoid arthritis and ulcerative colitis.
Chapters:
- (00:20) - Intro
- (00:58) - Veppanu
- (01:58) - Trimbow
- (03:13) - Xocova
- (04:28) - Zaynich
- (05:31) - Baxfendy
- (06:28) - Differin Epiduo Acne Gel
- (07:28) - Immgolis
- (08:06) - Outro
Follow Drugs.com:
- X, Facebook, YouTube
- Sign up to our newsletters
- Download the app
